Additional file 1 of Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Abstract

Additional file 1: Supplementary Figure 1. Plasma NTA-tau levels across AA criteria for staging AD using PET (BioFINDER-2). Supplementary Figure 2. Regional associations between plasma NTA-tau, p-tau181, NfL and GFAP levels with Aβ-PET, tau-PET and cortical thickness (BioFINDER-2). Supplementary Table 1. Characteristics of the subsample with available plasma t-tau (BioFINDER-2). Supplementary Table 2. Plasma NTA-tau levels by diagnosis (BioFINDER-2). Supplementary Table 3. Characteristics of the sample by AT status (BioFINDER-2). Supplementary Table 4. Plasma NTA-tau levels by AT status (BioFINDER-2). Supplementary Table 5. Characteristics of the sample by Braak stages (BioFINDER-2). Supplementary Table 6. Plasma NTA-tau levels by Braak stages (BioFINDER-2). Supplementary Table 7. Plasma NTA-tau levels by AA criteria for staging AD (BioFINDER-2). Supplementary Table 8. Plasma NTA-tau levels by diagnosis (BioFINDER-1). Supplementary Table 9. Comparison between models including/excluding an interaction between plasma NTA-tau and Aβ-status (BioFINDER-2 and -1). Supplementary Table 10. Proportion of variation of plasma biomarker levels explained by amyloid and tau (BioFINDER-2). Supplementary Table 11. Characteristics of the longitudinal tau-PET sample (BioFINDER-2). Supplementary Table 12. Characteristics of the longitudinal MRI sample (BioFINDER-2). Supplementary Table 13. Characteristics of the longitudinal MRI sample (BioFINDER-1). Supplementary Table 14. Characteristics of the longitudinal cognition sample (BioFINDER-2). Supplementary Table 15. Characteristics of the longitudinal cognition sample (BioFINDER-1). Supplementary Table 16. Characteristics of the longitudinal plasma NTA-tau (BioFINDER-1)